Our rigorously developed suite of computerized adaptive tests (CATs) delivers comprehensive, precise and real-time measurement of the impact of vision impairment and common blinding eye conditions. The technology is able to measure the effectiveness of eye treatment modalities, on multiple domains of patients’ quality of life (QoL).
This is the first of its kind in ophthalmology to allow healthcare providers to improve treatment and to provide better value-based care. Our CAT platform already hosts three valid and reliable eye-disease specific QoL CAT tests, for patients with:
diabetic retinopathy/diabetic macular edema,
general vision impairment.
TECHNOLOGY FEATURES & SPECIFICATIONS
Compared to paper-pencil questionnaires, CATs require fewer items and 50-90% less time to arrive at equally precise scores, reducing burden for busy clinics and clinical trials with a large testing protocol.
Key benefits of the technology include,
Fast measurement of QoL (2 mins per QoL domain),
High measurement precision due to the robust psychometric development of the CATs,
Comprehensive measurement of QoL, with multiple (>7) domains available,
Enables real-time feedback via automated scoring and integration with electronic health record systems,
Offers flexibility to administer CATs in clinic via a tablet or kiosk, or at home.
The primary application areas of our CAT technology are:
Healthcare – widespread collection of QoL data in patients attending tertiary eye centres
Industry – collection of QoL data as a study endpoint for clinical trials assessing the effectiveness of new treatment therapies developed by pharmaceutical companies
Our CAT technology can also be applied in:
Government agencies that require a disability assessment for people with vision impairment
Insurance companies to allocate reimbursements using ‘big data’ collected via widespread implementation of CATs in healthcare
Funded research and academia